Valuation Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.85 USD | -3.68% |
|
-4.79% | +11.49% |
Company Valuation: Arrowhead Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,509 | 3,498 | 2,880 | 2,408 | 4,769 | 10,800 | - | - |
| Change | - | -46.25% | -17.67% | -16.4% | 98.03% | 126.48% | - | - |
| Enterprise Value (EV) 1 | 6,141 | 3,390 | 2,769 | 2,305 | 3,961 | 9,820 | 9,894 | 10,086 |
| Change | - | -44.79% | -18.31% | -16.76% | 71.8% | 147.94% | 0.76% | 1.93% |
| P/E ratio | -45.9x | -19.8x | -14x | -3.87x | -3,449x | -24.3x | -18.8x | -27.2x |
| PBR | 15.9x | 8.79x | 10.6x | 13x | 10x | 24.9x | 34.3x | 94.1x |
| PEG | - | -0.9x | -0.9x | -0x | 34.6x | -0x | -0.6x | 0.9x |
| Capitalization / Revenue | 47.1x | 14.4x | 12x | 678x | 5.75x | 24.3x | 32.1x | 18.8x |
| EV / Revenue | 44.4x | 13.9x | 11.5x | 649x | 4.77x | 22.1x | 29.4x | 17.6x |
| EV / EBITDA | -43.6x | -20.2x | -14.4x | -3.96x | 32.4x | -28.4x | -22x | -33x |
| EV / EBIT | -41.2x | -19x | -13.5x | -3.84x | 40.3x | -23x | -17x | -23.8x |
| EV / FCF | 41.6x | -17.9x | -8.38x | -3.81x | 25.2x | -48.8x | -26.6x | -54.2x |
| FCF Yield | 2.4% | -5.57% | -11.9% | -26.2% | 3.96% | -2.05% | -3.76% | -1.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.36 | -1.67 | -1.92 | -5 | -0.01 | -3.158 | -4.087 | -2.816 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 138.3 | 243.2 | 240.7 | 3.551 | 829.4 | 444.1 | 336.7 | 573.1 |
| EBITDA 1 | -140.8 | -168.1 | -192.5 | -582.5 | 122.3 | -346.2 | -449.3 | -305.6 |
| EBIT 1 | -149 | -178.5 | -205 | -601.1 | 98.35 | -427.6 | -581.1 | -423.9 |
| Net income 1 | -140.8 | -176.1 | -205.3 | -599.5 | -1.631 | -449 | -592.1 | -412.1 |
| Net Debt 1 | -367.8 | -108 | -110.9 | -102.7 | -808 | -979.9 | -905.2 | -713.8 |
| Reference price 2 | 62.43 | 33.05 | 26.87 | 19.37 | 34.49 | 76.67 | 76.67 | 76.67 |
| Nbr of stocks (in thousands) | 104,259 | 105,849 | 107,193 | 124,315 | 138,258 | 140,857 | - | - |
| Announcement Date | 22/11/21 | 28/11/22 | 29/11/23 | 26/11/24 | 25/11/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -24.28x | 22.11x | -28.37x | -.--% | 10.8B | |
| 29.67x | 7.58x | 22.75x | 0.06% | 50.1B | |
| 17.07x | 5.18x | 11.33x | 1.74% | 45.82B | |
| -40.88x | 13.55x | -36.8x | -.--% | 23.66B | |
| -17.88x | 3.19x | -5.8x | -.--% | 22.65B | |
| 22.1x | 4.38x | 11.36x | -.--% | 17.8B | |
| 22.89x | 4.47x | 14.73x | -.--% | 16.08B | |
| 786.11x | 17.63x | 102.55x | -.--% | 14.14B | |
| -14.77x | 3857.46x | -19.13x | -.--% | 13.09B | |
| -440.28x | 31.6x | -1979.01x | -.--% | 13B | |
| Average | 33.98x | 396.71x | -190.64x | 0.18% | 22.71B | |
| Weighted average by Cap. | 29.03x | 231.44x | -104.53x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ARWR Stock
- Valuation Arrowhead Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition